Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C9FN
|
|||
| Drug Name |
PMID25666693-Compound-87
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23F2N3O3
|
|||
| Canonical SMILES |
CC(C)(C)C1=C(C=C(C=C1F)OCCNC(=O)C2=C3C=CC=C(N3N=C2)CO)F
|
|||
| InChI |
1S/C21H23F2N3O3/c1-21(2,3)19-16(22)9-14(10-17(19)23)29-8-7-24-20(28)15-11-25-26-13(12-27)5-4-6-18(15)26/h4-6,9-11,27H,7-8,12H2,1-3H3,(H,24,28)
|
|||
| InChIKey |
SNBOLRWYZPETPJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.